Used in targeted cancer therapies, particularly in inhibiting lymphangiogenesis and tumor metastasis. It blocks the VEGFR3 signaling pathway, which plays a key role in the formation of lymphatic vessels that tumors use to spread. This antibody is investigated in clinical trials for advanced solid tumors, including breast, lung, and colorectal cancers, often in combination with other anti-angiogenic or immunotherapeutic agents. Its high specificity allows for precise targeting of tumor-associated lymphatic endothelial cells, reducing unwanted effects on normal blood vessels. Also utilized as a research tool to study lymphatic system biology and tumor microenvironment interactions.